Stock VBIV VBI VACCINES INC.
Add to a list
To use this feature you must be a member
Log inSign up

News VBI Vaccines Inc.

Equities

VBIV

CA91822J2020

Delayed Nasdaq
Other stock markets
 01:10:37 2024-06-11 pm EDT 		5-day change 1st Jan Change
0.59 USD +0.85% Intraday chart for VBI Vaccines Inc. -0.86% +0.43%
May. 29 VBI Vaccines Inc. Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients CI
May. 22 VBI Vaccines Inc. Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
VBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients
BU
VBI Vaccines Inc. Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients
CI
VBI Vaccines Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients - VBI Vaccines
AQ
VBI Vaccines Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients
BU
VBI Vaccines Inc. Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients
CI
VBI Vaccines Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Earnings Flash (VBIV) VBI VACCINES Reports Q1 Revenue $1.2M
MT
VBI Vaccines Reports First Quarter 2024 Financial Results
BU
VBI Vaccines : 2023 Annual Report
PU
VBI Vaccines Reports Full Year 2023 Financial Results
BU
VBI Vaccines Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
North American Morning Briefing : Stock Futures -2-
DJ
VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
BU
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
BU
North American Morning Briefing : Inflation Data, -2-
DJ
VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma
BU
VBI Vaccines Inc. Presents Encouraging Early Tumor Response Data from Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma
CI
VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform - VBI Vaccines
AQ
VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform
BU
VBI Vaccines Inc. Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA- Launched eVLP Vaccine Platform
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VBIV Stock
  4. News VBI Vaccines Inc.